IBBQ
Invesco Nasdaq Biotechnology ETF
NASDAQ Biotechnology TR USD
NAV as of
4 Week: 19.50 - 20.84
52 Week: 16.94 - 22.17
Latest Closing Price
20.36
Premium / Discount
0.1
Expense Ratio
0.19%
Investment Objective
The investment seeks to track the investment results (before fees and expenses) of the Nasdaq Biotechnology Index ®. The fund generally will invest at least 90% of its total assets in the securities that comprise the index. Strictly in accordance with its guidelines and mandated procedures, Nasdaq compiles the underlying index, which is a modified market capitalization weighted index that is designed to measure the performance of securities listed on the Nasdaq Stock Market that are classified as either biotechnology or pharmaceutical companies. The index may include securities of large-, mid- and small-capitalization companies. The fund is non-diversified.
Main Fund Characteristics
Performance
Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
---|---|---|---|
YTD | -3.42 | 1.16 | -2.95 |
1 Day | -0.83 | 0.00 | 0.00 |
1 Week | 1.95 | 1.83 | 1.07 |
1 Month | -0.49 | 5.88 | -0.08 |
3 Months | -3.42 | 9.18 | -0.37 |
6 Months | 7.61 | 15.22 | 0.50 |
1 Year | -2.77 | 26.94 | -0.10 |
2 Years | 0.00 | 0.00 | 0.00 |
3 Years | 0.00 | 0.00 | 0.00 |
5 Years | 0.00 | 0.00 | 0.00 |
10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | |
Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | -10.2394 |
Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 41.0000 |
Dividend Frequency
Lastest Dividend
Ex Date | Payment Date | Dividend Payout per unit |
---|---|---|
18/12/2022 | 22/12/2022 | 0.0419 |
18/09/2022 | 22/09/2022 | 0.0377 |
20/06/2022 | 29/06/2022 | 0.0426 |
20/03/2022 | 28/04/2022 | 0.0378 |
19/12/2021 | 30/12/2021 | 0.1051 |
19/09/2021 | 29/09/2021 | 0.0432 |
Portfolio Data
Total Number of Holdings: 274
Number of Bond Holdings: 0
Number of Equity Holdings: 271
Total Market Value: 19,682,787
Portfolio Composition
Top 10 Holdings
% Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
---|---|---|---|---|---|
1 | Regeneron Pharmaceuticals Inc | 8.3473 | 2,005 | 0 | 1,642,797 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
Size | % of portfolio |
---|---|
Giant | 6.35 |
Large | 43.39 |
Medium | 26.60 |
Small | 13.18 |
Micro | 10.49 |
Equity Style Box Breakdown
0 | 0 | 0 | Large |
0 | 0 | 0 | Mid |
0 | 0 | 0 | Small |
Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
14.5700
Price/Book*
3.3007
Price/Sales*
3.0704
Price/Cash Flow*
12.5003
Dividend Yield*
0.9260
Growth Measures
Long-Term Earnings
7.4063
Historical Earnings
2.6015
Sales Growth
11.9896
Cash-Flow Growth
7.5857
Book-Value Growth
7.2175
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
Detail | Value |
---|---|
Average Effective Duration | 0 |
Average Effective Maturity (Years)* | 0 |
Average Credit Quality | 0 |
Average Weighted Coupon* | 0 |
Average Weighted Price* | 0 |
Bond Style Box Breakdown
0 | 0 | 0 | High | Quality |
0 | 0 | 0 | Med | |
0 | 0 | 0 | Low | |
Ltd | Mod | Ext | ||
Interest-Rate Sensitivity |
Credit Quality
Type | % Bonds |
---|---|
N.A |
Bond Sector
Bond Maturity
% Bonds | |
---|---|
N.A |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.